Gynecologic Cancer

 
Isabelle Laure Ray-Coquard, Aude Marie Savoye, Marie-ange Mouret-Reynier, et al.
The study authors conclude, that pembrolizumab may be safely added to preoperative treatment in patients deemed non-optimally resectable. The study met the primary objective with an improved complete Resection Rate on the carboplatin-paclitaxel + pembrolizumab arm. There was a higher than expected Complete Resection Rate in the control group. Clinical trial information: NCT03275506
 
 
Jacobus Pfisterer, Florence Joly, Gunnar Kristensen, et al.
The study authors conclude, that in these patients bevacizumab treatment duration of 15 months remains standard of care because for progression-free and overall survival there is no improvement with longer bevacizumab treatment for up to 30 months. Clinical trial information: NCT01462890
 
 
Rodney Paul Rocconi, Sharad A. Ghamande, Minal A. Barve, et al.
The study authors conclude that Vigil immunotherapy - Vigil is an autologous tumor cell vaccine transfected with a DNA plasmid encoding GMCSF and bi-shRNA-furin for TGFβ expression control - as frontline maintenance in Stage III/IV ovarian cancer is well tolerated. The treatment showed clinical benefit in both BRCA-wt and HRP molecular profile patients. Clinical trial information: NCT02346747
 
 
Janos Laszlo Tanyi, Hye Sook Chon, Mark Aloysuis Morgan, et al.
The study authors conclude, that the primary endpoint was met with pafolacianine sodium in intraoperative near-infrared fluorescence imaging, identifying additional cancer not planned for resection. They conclude that pafolacianine sodium may offer a novel real-time adjunct to current surgical imaging practice in ovarian cancer surgery. Clinical trial information: NCT03180307
 
 
David M. O'Malley, Ana Oaknin, Ursula A. Matulonis, et al.
The study authors demonstrate, that the combination of Mirvetuximab soravtansine (an ADC comprising a FRα-binding antibody) with bevacizumab demonstrates impressive anti-tumor activity with durable responses and favorable tolerability in high FRα recurrent ovarian cancer. These results suggest that Mirvetuximab soravtansine has the potential to be a preferred partner for bevacizumab in high FRα recurrent ovarian cancer regardless of platinum sensitivity. Clinical trial information: NCT02606305
 
 
Shannon Neville Westin, Robert L. Coleman, Bryan M. Fellman, et al.
The study authors demonstrated efficacy in patients with PARPi-resistant ovarian cancer with adavosertib given alone and in combination with olaparib. Grade 3 & 4 toxicities were observed on both arms, however, they were generally manageable with supportive care, dose interruptions and dose reductions as needed. Clinical trial information: NCT03579316
 
 
Paolo Zola, Giovannino Ciccone, Elisa Piovano, et al.
The study authors conclude, that intensive follow-up in endometrial cancer showed a weak and uncertain advantage in detecting earlier asymptomatic relapses.  These follow-ups did not improve overall survival, even in high-risk patients. Health-related quality of life was not improved. The authors discourage frequent routine use of imaging and laboratory exams in these patients. Clinical trial information: NCT00916708
 
 
Pierre-Etienne Heudel, Jean-Sebastien Frenel, Cécile Dalban, et al.
The study authors demonstrated a clinically and meaningful improvement with the anastrozole/vistusertib combination in 8w-and median progression-free survival with manageable toxicity. Clinical trial information: NCT02730923
 
 
Hussein Moustapha Ali-Ahmad, Michael Roth, Pam K. Mangat, et al.
The study authors demonstrated that Pertuzumab plus trastuzumab showed evidence of anti-tumor activity in heavily pre-treated uterine cancer patients with ERBB2 amplification or certain mutations. Clinical trial information: NCT02693535